MTOR and renal cell carcinoma: SCD1 expression is reported to stimulate following activation of PI3K-Akt-mTOR pathway in cancer cells [47] and therefore has been investigated as a therapeutic target in a variety of human cancers including colon [48, 49], endometrial [50], glioblastoma [51], lung [52], and renal cell carcinoma [53].